ABSTRACT: Rimonabant, the prototypic antagonist of cannabinoid CB1receptors, has been reported to have inverse agonist properties at higher concentrations, which may complicate its use as a tool for mechanistic evaluation of cannabinoid pharmacology. Consequently, recent synthesis efforts have concentrated on discovery of a neutral antagonist using a variety of structural ... Continue Reading
STUDY: Structural and pharmacological analysis of O-2050, a putative neutral cannabinoid CB1 receptor antagonist
